Emma L. Harvey, MBBS

Global Head of Medical Affairs
F2G Ltd
Egham, England, United Kingdom

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 870 - Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)

  Friday, October 21, 2022
  11:00 AM – 11:15 AM US ET

• 1618 - Olorofim - the first of a novel class of antifungals, the orotomides; F2G Inc

  Saturday, October 22, 2022
  8:20 AM – 8:30 AM US ET